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Abstract 1 
Dementia and type 2 diabetes are both characterized by long prodromal phases challenging the study of 2 
potential risk factors and their temporal relation. The progressive relation between metabolic syndrome, 3 
insulin resistance, and dementia has recently been questioned, wherefore the aim of this study was to 4 
assess the potential association between these precursors of type 2 diabetes and cognitive dysfunction. 5 
Using data from the Prospective Epidemiological Risk Factor study (n=2,103), a prospective study of 6 
elderly women in Denmark, we found that impaired fasting plasma glucose was associated with 44% 7 
(9%-91%) larger probability of developing cognitive dysfunction. In addition subjects above the 8 
HOMA-IR threshold (HOMA-IR > 2.6) had 47% (9%-99%) larger odds of cognitive dysfunction. The 9 
associations could indicate that a significant proportion of dementia cases in women is likely to be 10 
preventable by effective prevention and control of the insulin homeostasis. 11 
12 
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The sedentary western life-style has led to an epidemic-like increase in prevalence of obesity that is 1 
closely linked to occurrence of type 2 diabetes (1,2). Also the prevalence of cognitive dysfunction and 2 
dementia is increasing and epidemiological studies suggest an association between type 2 diabetes and 3 
increased risk of dementia and cognitive dysfunction (3). With metabolic syndrome (MetS) considered 4 
a precursor of type 2 diabetes (4) and central obesity and insulin resistance (IR) being recognized as 5 
important causative factors in the pathogenesis of MetS (5), a precursor state for dementia may be 6 
developed over several years.  7 
The long prodromal phases characterizing dementia and type 2 diabetes challenges the study of 8 
potential risk factors and their temporal relation (6,7) and in studies with short follow-up, putative 9 
relationships may be unreliable. Thus, reported associations between type 2 diabetes, MetS, and 10 
cognitive dysfunction are somewhat contrary. Until recently the brain was considered an insulin 11 
insensitive organ, it has however now been accepted that insulin, partly of peripheral origin, acts 12 
through its own receptors in the brain controlling cognition and memory(8). Thus it may be that IR is a 13 
condition affecting both peripheral and central insulin receptors with cerebral IR being part of a 14 
preclinical state of Alzheimer’s disease(9). Importantly, the temporal relation between MetS, IR, and 15 
cognitive dysfunction/dementia has recently been questioned (10,11). This prompted us to conduct the 16 
current study in which data obtained as part of The Prospective Epidemiological Risk Factor (PERF) 17 
study, a prospective study of Danish postmenopausal women (12), underwent an evaluation with the 18 
aim to study the hypothesis that there is a temporal relation between MetS and IR and cognitive 19 
dysfunction. Data from PERF were used to evaluate whether there is an association between the MetS 20 
or IR and cognitive impairment at a follow-up 15 years later including only subjects without signs of 21 
cognitive dysfunction at the baseline examination (n = 1759).  22 
23 
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Research design and Methods 1 
The Prospective Epidemiological Risk Factor Study 2 
The Prospective Epidemiological Risk Factor (PERF) Study, an observational, prospective cohort study 3 
of Danish postmenopausal women, was designed with the purpose to obtain knowledge of age-related 4 
diseases in postmenopausal women. The baseline examination (PERF I) took place between 1999 and 5 
2001 (n=5,855) and over fourteen months (from September 2013) 2,103 participants were included in a 6 
follow-up (PERF II) as described previously (12). The studies were carried out in accordance with 7 
ICH-GCP with study protocol approval from The Research Ethics Committee of Copenhagen County. 8 
Written informed consent was obtained from all subjects prior to any study related procedures. 9 
Study populations 10 
This study was based on all subjects that completed the follow-up examination, PERF II (n = 2,103) 11 
and from this population we identified the analytical sample as outlined in figure 1. 12 
(figure 1 here) 13 
The study population included all subjects with valid cognitive tests at baseline and follow-up. 14 
Exclusion criteria were cognitive dysfunction at baseline and missing data on any of the confounders 15 
included in the analysis. This qualified 1,759 subjects for the analysis.  16 
Cognitive dysfunction 17 
Two short cognitive screening tests were applied to assess cognitive function at baseline and follow-up. 18 
The Short Blessed Test (SBT) is a six-item test assessing orientation, concentration, and memory. The 19 
score ranges from 0 to 28, with lower scores indicating better performance. A threshold of ≥10 was 20 
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previously identified as cognitive impairment consistent with dementia (13). The category fluency test 1 
with animal naming (CFT) is a measure of verbal fluency where the subjects should name as many 2 
animals as possible in 60 seconds. Higher scores indicate better performance and the recommended 3 
threshold for dementia is ≤14 (14). 4 
Metabolic Syndrome at baseline 5 
MetS was defined using a modified version of the definition recommended by the International 6 
Diabetes Federation(15). Beside the entrance criteria of central obesity subjects should present two or 7 
more of the following risk factors: Increased triglycerides (>1.7 mmol/L), lowered level of HDL 8 
cholesterol (<1.29mmol/L), an increase in fasting plasma glucose (>5.6 mmol/L) or previously 9 
diagnosed type 2 diabetes, hypertension (systolic pressure above 130 mmHg or diastolic pressure 10 
higher than 85 mmHg or existing treatment of hypertension) to qualify for MetS. A direct measure of 11 
waist circumference was not obtained at baseline and therefore, the entrance criteria of central obesity 12 
was only defined by a BMI above 30 kg/m2 and as specific hyperlipidemia treatment was not part of 13 
the baseline questionnaire, we are unable to determine whether participants were on specific lipid-14 
lowering medication. 15 
Subjects without MetS were divided into three groups: i) subjects having a BMI >30kg/m2, and only 16 
one additional risk factor; ii) subjects presenting BMI <30kg/m
2 
but with 1-4 risk factors for MetS; and 17 
iii) subjects without any risk factors for MetS. This group was used as the reference group in the 18 
regression analysis. 19 
The homeostasis model assessment index 20 
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The homeostasis model assessment index (HOMA-IR) index was used to assess the degree of IR (16). 1 
The HOMA-IR index was calculated by fasting levels of plasma glucose multiplied by the 2 
concentration of insulin divided by the constant 22.5. Fasting plasma glucose was measured directly 3 
after collection in both PERF I and II, using a Vitros 250 slide cartridge with no reagent system from 4 
Ortho Clinical, in PERF I, and an enzymatic measurement method using the Avida 1800, from Siemens, 5 
in PERF II. Insulin levels at PERF I and PERF II was measured in thawed samples from the PERF 6 
biobank (stored at -80°C) on a Cobas e411 analyser from Roche. Blood samples were collected fasting 7 
in the morning.  8 
Statistical analysis 9 
Statistical analysis was conducted using R version 3.3.1 (R Foundation for Statistical Computing, 10 
Vienna, Austria). Spearman's Rank-Order Correlation was used to measure the association between 11 
scores of the two cognitive tests. By use of the glm function, logistic regression assessed the association 12 
between risk factors for the MetS, metabolic profiles and cognitive dysfunction. Three separate 13 
multivariable analyses were completed. In all analyses, baseline age and baseline cognitive 14 
performance were included as continuous variable and education level (primary school/high 15 
school/university), smoking history (never/former/current), alcohol consumption (none/<10.5 alcohol 16 
units per week/10.5-21 alcohol units per week/>21 alcohol units per week) and physical activity 17 
(Inactive/1 time per Week/2 times per Week/3+ times per week) and current use of hormone 18 
replacement therapy (yes/no) as categorical covariates.  19 
We first tested each of the single risk factors comprising the MetS. The variables were dichotomized as 20 
described under “Metabolic Syndrome at baseline” above. Using the dichotomized variables we then 21 
studied how metabolic profiles at baseline were associated with cognitive dysfunction. First, we used 22 
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the modified definition of MetS followed by the cumulative sum of MetS risk factors, ranging from 1 
zero to five, then we assessed the association between IR and risk of cognitive dysfunction. The 2 
baseline HOMA-IR index was used as continuous variable and further dichotomized at 2.6, where 3 
subjects above the threshold was considered insulin resistant. The outcome variables used were i) 4 
cognitive dysfunction on the SBT (SBT≥10), ii) cognitive dysfunction on the CFT (CFT≤14), and iii) 5 
cognitive dysfunction on both SBT and CFT (SBT≥10 and CFT≤14). 6 
The Hosmer-Lemeshow test was used to test the goodness of fit for the logistic regression models.  7 
Results 8 
Of the 1,759 subjects included in the analysis, 136 had cognitive dysfunction according to the SBT, 9 
while 326 were classified with cognitive dysfunction when it was determined by CFT. A total of 80 10 
subjects showed signs of cognitive dysfunction on both tests.  11 
Characteristics of the study population 12 
The baseline characteristics of the study population is shown in table 1. All subjects were on average 13 
68 years old at baseline, with the non-impaired group as the youngest and the group of subjects with 14 
impaired cognition on both tests as the oldest.  15 
(table 1 here) 16 
There was a negative correlation between scores in the SBT and the CFT (rho = -0.294 [-0,336 to -17 
0,250], p <0.0001).   18 
The association between Metabolic Syndrome, Insulin resistance and cognitive dysfunction 19 
Page 7 of 23 Diabetes
8 
 
Table 2 shows the association between metabolic risk factors, MetS, IR and cognitive dysfunction at 1 
follow-up. Fasting plasma glucose was associated with impairment in CFT suggesting that 2 
hyperglycemia increases the risk for development of cognitive dysfunction with 44% (OR 1.44, 95% 3 
CI 1.09-1.91). Having from one to four metabolic risk factors did not significantly alter the risk of 4 
cognitive dysfunction at follow-up when compared to subjects with no risk factors. In subjects with the 5 
worst metabolic profile, holding all five risk factors for MetS, the risk for cognitive dysfunction on 6 
verbal fluency was three times higher (OR 3.09, 95% CI 1.09-8.69) as compared to subjects who did 7 
not present any of the MetS risk factors. MetS was however not associated with increased risk of 8 
cognitive dysfunction at follow-up. 9 
(table 2 here)  10 
IR was associated with an increased risk of cognitive dysfunction, calculated both as CFT and a 11 
combination of the SBT and the CFT (Table 2). The risk of cognitive dysfunction increased between 8-12 
10% for every unit increase on the HOMA-IR index scale and when dichotomized, subjects above the 13 
threshold of 2.6 had a 47% higher risk of cognitive dysfunction on verbal fluency (OR 1.47, 95% CI 14 
1.09-1.99) as compared to subjects below the HOMA-IR threshold. 15 
16 
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Discussion 1 
In the present study we assessed the temporal relation between biomarkers and precursors of type 2 2 
diabetes and cognitive dysfunction and specifically we evaluated whether MetS and IR are associated 3 
with development of cognitive dysfunction. Based on data with a follow-up period of up to 15 years it 4 
is demonstrated that i) subjects with impaired fasting plasma glucose have larger odds of developing 5 
cognitive dysfunction and ii) subjects with IR as determined by the HOMA-IR index have higher 6 
probability of developing cognitive dysfunction. While fasting plasma glucose were specifically 7 
associated with dysfunction on the verbal fluency test, IR seemed to result in more global cognitive 8 
dysfunction as determined by a combination of two short cognitive screening tests. The third important 9 
finding is that subjects with a poor metabolic profile, reflected by the presence of several metabolic and 10 
cardiovascular risk factors, have a 3- to 4-fold larger odds of developing cognitive dysfunction than 11 
subjects with an ideal metabolic profile. Overall the data suggest that IR is a cause rather than a 12 
consequence of cognitive dysfunction. 13 
Fasting plasma glucose was the single metabolic risk factor that was most strongly associated with 14 
cognitive dysfunction. With cognitive function assessed by the CFT, subjects with impaired fasting 15 
plasma glucose levels had a 44% (9%-91%) larger odds of cognitive dysfunction as compared to 16 
normoglycemic subjects. While presence of MetS in itself does not seem to provoke an elevated risk of 17 
cognitive dysfunction, subjects with a poor metabolic profile have a three to four time’s larger odds of 18 
developing cognitive dysfunction when compared to subjects with an ideal metabolic profile. The 19 
Framingham cohort have recently shown that subjects with ideal cardiovascular health, determined 20 
from a 7-point scale proposed by the American Heart Association, are at lower risk of dementia, 21 
cognitive decline and brain atrophy(17). Out of the seven risk factors defining an ideal cardiovascular 22 
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health profile, four is identical or at least very similar to those defining the MetS, suggesting that 1 
cardiovascular and metabolic health is closely linked to brain health.  2 
Peripheral IR has been shown to alter the transport of insulin through the blood-brain barrier. The 3 
insulin transport is reduced by peripheral hyperinsulinemia (18), which can directly contribute to 4 
cognitive impairment and promote AD pathology(19,20). It has also recently been shown that IR 5 
predicts worse memory performance through a reduction in regional cerebral glucose metabolism (21), 6 
supporting IR being a causal risk factor for development of cognitive dysfunction. While the study 7 
design does not allow for causal conclusions, the data presented here can be taken to indicate a 8 
temporal relation between IR and cognitive dysfunction. However, we cannot rule out the possibility 9 
that dementia or cognitive dysfunction leads to a diabetic phenotype and that a disturbance in insulin 10 
homeostasis, as a secondary process, may accelerate certain dementia pathologies (22). IR may be a 11 
shared underlying pathological mechanism, since it is part of the prodromal phase of both type 2 12 
diabetes and dementia. Interestingly amyloid formation is a pathological hallmark of both type 2 13 
diabetes and AD: islet amyloid polypeptide is found in the pancreas of subjects with type 2 diabetes 14 
and β-amyloid is in the brain of subjects with AD (23). A recent study even suggest that pancreatic 15 
derived amyloid may enter the brain and exacerbate the disposition of β-amyloid through cross-seeding 16 
(24). 17 
There are previous studies indicating an association between sleep disturbances and dementia (25). 18 
Mechanisms underlying the association are many, and IR is speculated to play an important role, 19 
however the causal link has not been elucidated. The menopausal transition is associated with sleep 20 
disturbances, which are also found to increase the risk of type 2 diabetes (26,27). As we observed a link 21 
between IR and cognitive dysfunction, it could indicate that IR is an intermediate mechanism for the 22 
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causal association between sleep disturbances and cognitive dysfunction. We can however not address 1 
this in the current study as we did not collect information on sleep disturbances and sleep patterns at 2 
baseline. 3 
The small, albeit significant, correlation between the two tests was expected and indicate that the two 4 
tests are not equivalent. This was reflected in the observed domain-specific effect of fasting plasma 5 
glucose and IR on cognition specifically related to verbal fluency. A similar domain-specific effect on 6 
verbal fluency has previously been found in two cross-sectional studies (28,29). One of the studies 7 
found that the effect of IR on cognition was modulated by gender, indicating that IR was associated 8 
with poor performance on verbal fluency only in women. Verbal fluency performance is functionally 9 
linked to the frontal and temporal lobe areas. These brain areas rich in insulin receptors, are found to be 10 
associated with memory function(28,30). There are several neuropathological conditions that affect 11 
memory-related areas in the brain, with AD being one of them. A structural alteration of semantic 12 
networks located in the frontal and temporal lobe areas has been found to be characteristic for AD even 13 
in the early stages of AD (31,32). 14 
The concept of precision medicine is emerging in relation to prevention and treatment of AD (33) and 15 
the abundant evidence of various AD phenotypes, the metabolic phenotype being one, suggests that it 16 
is extremely relevant in this field. A recent meta-analysis indicate that insulin sensitizer drugs, like 17 
metformin and thiazolinediones, might be useful in the prevention of dementia in diabetic patients (34). 18 
Whether there is a direct mechanistic link is still controversial, but evidence from rat studies have 19 
shown that the glucagon-like peptide 1 analog liraglutide, another insulin sensitizer, interacts directly 20 
with processes leading to amyloid plaques and neurofibrillary tangles, the two pathological hallmarks 21 
of AD (35,36). Moreover, clinical trials have shown promising effects of intranasal insulin in subjects 22 
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with AD and its prodrome, mild cognitive impairment (37,38) and also on spatial memory in young 1 
men (39).  2 
The analysis was restricted to subjects attending the follow-up examination, therefore selection bias 3 
may affect the internal validity and question the generalizability of our results as it is well-known that 4 
cognitive dysfunction and dementia affect attrition. We have previously assessed the similarities 5 
between follow-up participants and follow-up non-participants on a cohort level, and found that the two 6 
populations are very similar (12). This should strengthen the internal validity. Further, we based our 7 
determination of cognitive dysfunction on two short cognitive screening tools at the follow-up visit, 8 
therefore we cannot not rule out the possibility that cognitive dysfunction in the current study may be 9 
caused by reversible conditions and thereby potentially result in misclassification. The diagnostic 10 
accuracy of the two tests in relation to dementia is excellent (40–43). They have even been shown to 11 
outperform more comprehensive tests like the Mini Mental State Examination in the identification of 12 
milder levels of impairment (44,45). In the absence of a comprehensive diagnostic workup with a 13 
complete neuropsychological test battery, this evidence support the use of these simple tests. 14 
Another limitation is the lack of repeated measurement of glucose, insulin and cognition throughout the 15 
follow-up period as it would allow for a better assessment of the mutual trajectories and also resulted in 16 
a more accurate determination of the onset of cognitive dysfunction. Given the previously reported 17 
interconnection between genetic and metabolic risk factors, the lack of genetic risk factors in our 18 
studies is a limitation that could result in unmeasured confounding. For example it has been suggested 19 
that the insulin metabolism may differ between Apolipoprotein E epsilon 4 allele carriers and non-20 
carriers (46). 21 
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Conclusion 1 
The precursors of type 2 diabetes; impaired fasting plasma glucose and IR, are associated with 2 
increased risk of developing cognitive dysfunction in elder women. Moreover, subjects with a poor 3 
metabolic profile are more likely to develop cognitive dysfunction than subjects with an ideal 4 
metabolic profile. If the observed association between metabolic risk factors and cognitive dysfunction 5 
is truly causal it could suggest that a significant proportion of dementia cases in women may be 6 
preventable by effective control of insulin homeostasis.  7 
8 
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Tables 1 
Table 1: Baseline characteristics of the study population.  Numbers are shown as absolute numbers 2 
with percentile in brackets for categorical variables. For numerical variables the mean ± standard 3 
deviation (SD) are shown. 4 
Variable 
Non 
impaired 
n = 1377 
SBT ≥ 10 
n = 136 
CFT ≤ 14 
n = 326 
SBT ≥ 10 
CFT ≤ 14 
n = 80 
Demographics             
Age (years) 66.9 ± 5.6 70.6 ± 6.5 70.5 ± 5.8 72.4 ± 5.7 
Education:  Primary school, n (%) 903 (65.6) 96 (70.6) 225 (69.0) 56 (70.0) 
     High School, n (%) 332 (24.1) 26 (19.1) 77 (23.6) 17 (21.2) 
     University, n (%) 142 (10.3) 14 (8.1) 24 (7.4) 7 (8.8) 
Lifestyle             
BMI (kg/m2) 26.0 ± 4.0 26.3 ± 4.8 26.5 ± 4.4 26.3 ± 4.3 
     <18,5, n (%) 19 (1.2) 1 (0.7) 2 (0.6) 0 
     18,5-24,9, n (%) 686 (42.3) 63 (46.3) 133 (40.8) 36 (45.0) 
     25,0-29,9, n (%) 653 (40.2) 46 (33.8) 127 (39.0) 28 (35.0) 
     ≥30,0, n (%) 265 (16.3) 26 (19.1) 64 (19.6) 16 (20.0) 
Smoking History: Never, n (%) 723 (52.5) 68 (50.0) 167 (51.2) 45 (56.2) 
     Former, n (%) 403 (29.3) 41 (30.1) 89 (27.3) 23 (28.7) 
     Current, n (%) 251 (18.2) 27 (19.9) 70 (21.5) 12 (15.0) 
Alcohol: None, n (%) 512 (37.2) 66 (48.5) 148 (45.4) 36 (45.0) 
     <10.5 alcohol units/week, n (%) 312 (22.7) 22 (16.2) 61 (18.7) 15 (18.8) 
     10.5–21 alcohol units/week, n (%) 423 (30.7) 38 (27.9) 89 (27.3) 22 (27.5) 
     >21 alcohol units/week, n (%) 130 (9.4) 10 (7.4) 28 (8.6) 7 (8.8) 
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Physical activity: Inactive, n (%) 306 (22.2) 40 (29.4) 103 (31.6) 22 (27.5) 
     1 time /week, n (%) 310 (22.5) 29 (21.3) 54 (16.6) 17 (21.2) 
     2 times/week, n (%) 204 (14.8) 18 (13.2) 48 (14.7) 11 (13.8) 
     3+ times/week, n (%) 557 (40.5) 49 (36.0) 697 (37.1) 30 (37.5) 
Metabolic and Vascular factors             
Systolic Blood Pressure (mmHg) 145.5 ± 23.1 148.9 ± 23.7 148.8 ± 23.2 150.2 ± 23.9 
Diastolic Blood Pressure (mmHg) 81.9 ± 10.5 82.0 ± 10.5 82.0 ± 11.0 81.5 ± 10.8 
Fasting Plasma Glucose (mmol/L) 5.4 ± 1.0 5.6 ± 1.5 5.6 ± 1.1 5.8 ± 1.8 
Insulin (mmol/L) 54.9 ± 34.6 58.7 ± 44.5 60.9 ± 38.8 61.5 ± 42.1 
HOMA-IR 2.0 ± 1.5 2.4 ± 3.6 2.3 ± 2.6 2.6 ± 4.3 
High density lipoprotein (mmol/L) 1.7 ± 0.4 1.7 ± 0.4 1.8 ± 0.5 1.8 ± 0.4 
Triglycerides (mmol/L) 1.3 ± 0.6 1.4 ± 0.7 1.4 ± 0.7 1.4 ± 0.7 
Cognitive performance             
Short Blessed Test 1.3 ± 1.9 2.4 ± 2.4 1.7 ± 2.1 2.4 ± 2.3 
Category Fluency Test 24.3 ± 5.2 21.5 ± 4.5 20.6 ± 4.2 20.8 ± 4.4 
 1 
2 
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Table 2: Association between Metabolic Syndrome, Insulin resistance and cognitive dysfunction 1 
Predictor variables 
  Cognitive status at follow up 
SBT ≥10 CFT ≤14 
SBT ≥10 & 
CFT≤14 
  OR* 95% CI   OR* 95% CI OR* 95% CI 
Individual Component of the MetS                               
  Body Mass Index  (>30kg/m2) 1.22 0.76 - 1.94 1.24 0.88 - 1.74 1.26 0.70 - 2.30 
  Elevated Blood Pressure  0.88 0.56 - 1.38 1.07 0.76 - 1.50 0.68 0.38 - 1.23 
  Impaired Fasting Plasma Glucose  1.12 0.76 - 1.64 1.44 1.09 - 1.91 1.56 0.96 - 2.52 
  Low High Density Lipoprotein 1.01 0.59 - 1.74 1.19 0.81 - 1.74 0.99 0.47 - 2.09 
  Elevated Triglycerides 1.25 0.81 - 1.91 0.98 0.71 - 1.36 1.09 0.61 - 1.95 
Cumulative sum of risk factors for MetS       
 
                      
  0 risk factors reference 
  1 " 0.72 0.40 - 1.27 1.02 0.65 - 1.59 0.72 0.34 - 1.56 
  2 " 0.64 0.35 - 1.19 1.06 0.66 - 1.69 0.60 0.27 - 1.38 
  3 " 1.18 0.61 - 2.27 1.19 0.70 - 2.03 1.02 0.41 - 2.52 
  4 " 0.59 0.22 - 1.60 1.39 0.71 - 2.71 0.66 0.19 - 2.33 
  5 " 2.56 0.75 - 8.79 3.07 1.09 - 8.69 4.35 1.02 - 18.6 
Metabolic Syndrome       
 
                      
  No MetS reference 
  Risk factors for MetS with BMI < 30 kg/m2 0.98 0.65 - 1.49 1.08 0.80 - 1.46 0.94 0.55 - 1.61 
  BMI  >30kg/m2 and < 2 risk factors 1.11 0.53 - 2.33 1.30 0.77 - 2.19 1.61 0.69 - 3.77 
  Metabolic Syndrome   1.28 0.71 - 2.29   1.30 0.82 - 1.94   1.18 0.55 - 2.55 
Insulin Resistance (HOMA-IR)       
 
                      
  Dichotomized (HOMA-IR > 2.6) 
 
0.98 0.64 - 1.52 1.47 1.09 - 1.99 
 
1.33 0.77 - 2.27 
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  Continuous (per unit increase)   1.05 0.98 - 1.13   1.08 1.01 - 1.16   1.10 1.01 - 1.19 
 *Odds ratios were adjusted for Age at Baseline, Smoking history, Alcohol Consumption, Physical Activity, Education and 
Hormone replacement therapy 
 
   
  1 
2 
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Figure legends 1 
Figure 1: Flowchart for the identification of the analytical sample. Each outcome was determined 2 
independent of the other outcomes. SBT: Short Blessed Test, CFT: Category Fluency test. 3 
 4 
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